New Tax Rules Won’t Stop Pfizer From Bidding U.S. Goodbye CEO says there is still value to moving its headquarters out of the U.S.

New Tax Rules Won’t Stop Pfizer From Bidding U.S. Goodbye CEO says there is still value to moving its headquarters out of the U.S.

Pfizer has been on the hunt for a multibillion-dollar deal that would add to the New York-based drugmaker’s pipeline, cut costs, and help it escape the U.S.’s 35% corporate tax rate. Under the strategy called inversion, U.S. companies use mergers to shift their legal address to a lower-tax country without moving their operations.

The ideal transaction has all three components, though U.S. Treasury Department rules announced last month could lower the value Pfizer assigns to the tax advantages. A tax inversion isn’t required for a deal

http://www.bloomberg.com/news/2014-10-28/pfizer-lowers-full-year-sales-guidance-on-competition.html?alcmpid=markets

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s